GTx, Inc.: Company Profile and SWOT Analysis

Document Sample
GTx, Inc.: Company Profile and SWOT Analysis Powered By Docstoc
					GTx, Inc.

_________________________________________________________________________________



GTx, Inc.                                                                         Financial Snapshot

                                                                                  Operating Performance
Fast Facts
                                        3 N. Dunlap Street, 3rd Floor, Memphis,   The company reported revenues of US$60.61 million
Headquarters Address
                                        38163                                     during 2010, with a CAGR of 68.58% during 2006–
                                                                                  2010. Its revenue grew at an annual rate of 311.49%
Telephone                               + 1 901 5239700
                                                                                  over the previous fiscal year. In 2010, the company
                                                                                  recorded an operating margin of 22.98%, as against -
Fax                                     + 1 901 6448075                           316.92% in 2009.

Website                                 www.gtxinc.com
                                                                                  Revenue and Margins
Ticker Symbol, Stock Exchange           GTXI, NASDAQ

Number of Employees                     111

Fiscal Year End                         December

Revenue (in US$ million)                60.61




SWOT Analysis

Strengths                               Weaknesses                                Return on Equity

Strong liquidity position               Lack of manufacturing facilities          The company recorded a return on equity (ROE) of
                                                                                  29.57% for 2010, as compared to its peers, Eli Lilly
                                        Termination of collaboration agreement    and Company (Ticker: LLY), Amgen Inc. (Ticker:
Strong Product - FARESTON                                                         AMGN) and Pfizer Inc. (Ticker: PFE), which recorded
                                        with Ipsen
                                                                                  ROEs of 40.82%, 19.32% and 9.40% respectively.
Strong R&D focus                                                                  The company reported an operating margin of
                                                                                  22.98% in 2010.
Opportunities                           Threats
                                                                                  Return on Equity
Changing demographics                   FDA’s regulatory oversight

Growing prevalence of cancer            Intense competition

Potential for cancer cachexia treatment Pricing of drugs




                                                                                  Liquidity Position

                                                                                  The company reported a current ratio of 11.38 in
                                                                                  2010, as compared to its peers, Eli Lilly and
                                                                                  Company, Amgen Inc. and Pfizer Inc., which recorded
                                                                                  current ratios of 2.09, 3.52 and 2.11 respectively. As
                                                                                  of December 2010, the company recorded cash and
                                                                                  short-term investments of worth US$58.63 million,
                                                                                  against zero current debt. The company reported a
                                                                                  debt to equity ratio of 0.00 in 2010 as compared to its
                                                                                  peers, Eli Lilly and Company, Amgen Inc. and Pfizer
                                                                                  Inc., which recorded debt to equity ratios of 0.56, 0.56
                                                                                  and 0.50 respectively.




___________________________________________________________________________________________

GTx, Inc. - SWOT Profile                                                                                                   Page 1
GTx, Inc.

_________________________________________________________________________________


TABLE OF CONTENTS

1     Business Analysis ................................................................................................................................... 5
    1.1       Company Overview ................................................................................................................................................5
    1.2       Business Description ..............................................................................................................................................5
    1.3       Major Products and Services .................................................................................................................................6
    1.4       Key Financial Performance Indicators ...................................................................................................................7
      1.4.1       Revenue and Operating Profit ...........................................................................................................................7
      1.4.2       Asset, Liabilities and Capex ...............................................................................................................................8
      1.4.3       Operational Efficiency ........................................................................................................................................9
      1.4.4       Valuation ..........................................................................................................................................................10
    1.5       Competitive Benchmarking ..................................................................................................................................11
      1.5.1       Market Capitalization .......................................................................................................................................11
      1.5.2       Efficiency ..........................................................................................................................................................12
      1.5.3       Capital Expenditure ..........................................................................................................................................13
      1.5.4       Valuation ..........................................................................................................................................................14
      1.5.5       Turnover – Inventory and Asset .......................................................................................................................15
2     Recent Developments ........................................................................................................................... 16
3     SWOT Analysis ...................................................................................................................................... 18
    3.1       SWOT Analysis - Overview ..................................................................................................................................18
    3.2       Strengths ..............................................................................................................................................................18
    3.3       Weaknesses .........................................................................................................................................................18
    3.4       Opportunities ........................................................................................................................................................19
    3.5       Threats ......................................
				
DOCUMENT INFO
Description: This SWOT analysis and company profile is a crucial resource for industry executives and anyone looking to gain a better understanding of the company's business. ICD Research's "GTx, Inc.: Company Profile and SWOT Analysis" report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
BUY THIS DOCUMENT NOW PRICE: $99 100% MONEY BACK GUARANTEED
PARTNER ICD Research
With emphasis on Insight, Consultancy and Delivery, iCD Research is a full-service, online market research agency. iCD Research is able to take advantage of all of the efficiencies and benefits that the Internet brings to offer proven research methodologies with fast turnaround and accurate results. iCD Research specialises in qualitative research for large finance, media, retail and entertainment clients. Market leaders in online focus groups, iCD Research has unleashed the full scale of the Internet to run focus groups across the globe for its major institutional clients. Utilising its sister organisation, The iD Factor, iCD Research also delivers strong quantitative research, ranging from ongoing consumer confidence studies through to consumer surveys throughout Europe and Asia. With its roots firmly in research, iCD Research doesn’t limit itself to only utilising online methods as the philosophy at the company is to match the methodology to the respondent. Yet the scale and speed of online research give iCD Research a cutting edge that has lead to tremendous, triple-figure percentage growth over the past two years. iCD Research is headquartered in London, with operational offices in the US and Australia to ensure that it is offering an unparalleled 24 hour service to its clients.